SecBot SecBot
SECBOTREPLAY Home › Report › GRFS

GRFS · Grifols announced completion of the clinical portion (last patient,…

Grifols, S.A. · PRESS-RELEASE filed Aug 10, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Aug 10, 2026 at 07:00 ET

Grifols announced completion of the clinical portion (last patient, last visit) of its Phase 3 SPARTA trial evaluating Prolastin-C in alpha-1 antitrypsin deficiency patients with emphysema. Topline results are expected by the end of 2026. This is a pipeline milestone with no financial data or efficacy readout yet.

  • SPARTA Phase 3 trial completed last-patient-last-visit; topline results expected by end of 2026.
  • Trial enrolled 345 participants across 37 sites in 16 countries.
  • Evaluates two dose regimens of Prolastin-C (60 mg/kg and 120 mg/kg) vs placebo over three years.
  • Primary endpoint is whole-lung CT densitometry, a sensitive measure of emphysema progression.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access